Interactions between Baxdrostat and Hemorid Ointment

The phenylephrine topical in Hemorid Ointment has a moderate potential interaction with Benign Prostatic Hyperplasia.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

The phenylephrine topical in Hemorid Ointment has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

The phenylephrine topical in Hemorid Ointment has a moderate potential interaction with Cerebrovascular Insufficiency.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

Baxdrostat has a moderate potential interaction with Diabetes Mellitus.

Baxdrostat can cause hyperkalemia. Correct serum potassium abnormalities prior to initiation. More frequent monitoring is recommended for patients 65 years and older, those with diabetes mellitus or chronic kidney disease, and those receiving concomitant medications that increase serum potassium.

The phenylephrine topical in Hemorid Ointment has a moderate potential interaction with Diabetes Mellitus.

Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use. Slight increases in blood glucose concentrations may occur with the use of these drugs. Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of the individual products not be exceeded.

Baxdrostat has a moderate potential interaction with Hyperkalemia.

Baxdrostat can cause hyperkalemia. Correct serum potassium abnormalities prior to initiation. More frequent monitoring is recommended for patients 65 years and older, those with diabetes mellitus or chronic kidney disease, and those receiving concomitant medications that increase serum potassium.

The phenylephrine topical in Hemorid Ointment has a moderate potential interaction with Hyperthyroidism.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. The use of topical sympathomimetic agents has rarely been associated with palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion. Therapy with topical sympathomimetic agents should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension.

Baxdrostat has a moderate potential interaction with Hyponatremia.

Baxdrostat can cause hyponatremia. Correct serum sodium abnormalities prior to initiation. More frequent monitoring is recommended for patients with low baseline serum sodium concentrations.

Baxdrostat has a moderate potential interaction with Liver Disease.

Baxdrostat has not been studied in patients with severe hepatic impairment.

The phenylephrine topical in Hemorid Ointment has a moderate potential interaction with Prostate Tumor, Benign.

Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

Baxdrostat has a moderate potential interaction with Renal Dysfunction.

Safety and effectiveness of baxdrostat have not been established in patients with estimated GFR less than 45 mL/min/1.73 m2.

Baxdrostat has a moderate potential interaction with Renal Dysfunction.

Baxdrostat can cause hyperkalemia. Correct serum potassium abnormalities prior to initiation. More frequent monitoring is recommended for patients 65 years and older, those with diabetes mellitus or chronic kidney disease, and those receiving concomitant medications that increase serum potassium.